(Q85032624)

English

Serum miRNA‐21: Elevated levels in patients with metastatic hormone‐refractory prostate cancer and potential predictive factor for the efficacy of docetaxel‐based chemotherapy

scientific article published on September 14, 2010

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20842666%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20842666%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Serum miRNA‐21: Elevated levels in patients with metastatic hormone‐refractory prostate cancer and potential predictive factor for the efficacy of docetaxel‐based chemotherapy (English)

1 reference

10.1002/PROS.21246

https://api.crossref.org/works/10.1002/PROS.21246

13 July 2024

prostate cancer

1 reference

based on heuristic

inferred from title

author name string

Hai-Liang Zhang

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20842666%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Li-Feng Yang

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20842666%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Yao Zhu

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20842666%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Xu-Dong Yao

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20842666%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Shi-Lin Zhang

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20842666%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Bo Dai

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20842666%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Yi-Ping Zhu

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20842666%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Yi-Jun Shen

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20842666%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Guo-Hai Shi

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20842666%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Ding-Wei Ye

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20842666%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20842666

13 July 2024

publication date

14 September 2010

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20842666%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

full work available at URL

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fpros.21246

1 reference

10.1002/PROS.21246

https://api.crossref.org/works/10.1002/PROS.21246

13 July 2024

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pros.21246

1 reference

10.1002/PROS.21246

https://api.crossref.org/works/10.1002/PROS.21246

13 July 2024

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20842666%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

71

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20842666%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20842666%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

326-331

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20842666%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Cancer statistics, 2009

1 reference

28 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.3322/CAAC.20006

MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer

1 reference

30 December 2023

https://opencitations.net/index/api/v1/citations/10.1016/J.YGYNO.2008.04.033

Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I: international comparisons

1

1 reference

10.1002/PROS.21246

https://api.crossref.org/works/10.1002/PROS.21246

13 July 2024

Cancer incidence and mortality in Europe, 2004

2

1 reference

10.1002/PROS.21246

https://api.crossref.org/works/10.1002/PROS.21246

13 July 2024

Management of prostate cancer in China: a multicenter report of 6 institutions

4

1 reference

10.1002/PROS.21246

https://api.crossref.org/works/10.1002/PROS.21246

13 July 2024

EAU guidelines on prostate cancer

7

1 reference

10.1002/PROS.21246

https://api.crossref.org/works/10.1002/PROS.21246

13 July 2024

Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer

8

1 reference

10.1002/PROS.21246

https://api.crossref.org/works/10.1002/PROS.21246

13 July 2024

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

9

1 reference

10.1002/PROS.21246

https://api.crossref.org/works/10.1002/PROS.21246

13 July 2024

MicroRNA in cancer prognosis

10

1 reference

10.1002/PROS.21246

https://api.crossref.org/works/10.1002/PROS.21246

13 July 2024

MiRNAs and cancer

11

1 reference

10.1002/PROS.21246

https://api.crossref.org/works/10.1002/PROS.21246

13 July 2024

MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells

12

1 reference

10.1002/PROS.21246

https://api.crossref.org/works/10.1002/PROS.21246

13 July 2024

MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis

13

1 reference

10.1002/PROS.21246

https://api.crossref.org/works/10.1002/PROS.21246

13 July 2024

MicroRNA involvement in hepatocellular carcinoma

14

1 reference

10.1002/PROS.21246

https://api.crossref.org/works/10.1002/PROS.21246

13 July 2024

miR-21 plays a pivotal role in gastric cancer pathogenesis and progression

15

1 reference

10.1002/PROS.21246

https://api.crossref.org/works/10.1002/PROS.21246

13 July 2024

MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma

16

1 reference

10.1002/PROS.21246

https://api.crossref.org/works/10.1002/PROS.21246

13 July 2024

MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer

17

1 reference

10.1002/PROS.21246

https://api.crossref.org/works/10.1002/PROS.21246

13 July 2024

Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells

18

1 reference

10.1002/PROS.21246

https://api.crossref.org/works/10.1002/PROS.21246

13 July 2024

MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene

19

1 reference

10.1002/PROS.21246

https://api.crossref.org/works/10.1002/PROS.21246

13 July 2024

miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth

20

1 reference

10.1002/PROS.21246

https://api.crossref.org/works/10.1002/PROS.21246

13 July 2024

Serum microRNAs are promising novel biomarkers

21

1 reference

10.1002/PROS.21246

https://api.crossref.org/works/10.1002/PROS.21246

13 July 2024

Circulating MicroRNA Signatures of Tumor-Derived Exosomes for Early Diagnosis of Non-Small-Cell Lung Cancer

23

1 reference

10.1002/PROS.21246

https://api.crossref.org/works/10.1002/PROS.21246

13 July 2024

Circulating microRNAs as stable blood-based markers for cancer detection

24

1 reference

10.1002/PROS.21246

https://api.crossref.org/works/10.1002/PROS.21246

13 July 2024

Docetaxel plus prednisone versus mitoxantrone plus prednisone for metastatic hormone-refractory prostate cancer in Chinese patients: experience of a single center

25

1 reference

10.1002/PROS.21246

https://api.crossref.org/works/10.1002/PROS.21246

13 July 2024

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

26

1 reference

10.1002/PROS.21246

https://api.crossref.org/works/10.1002/PROS.21246

13 July 2024

Isolation of cell-free RNA from maternal plasma

27

1 reference

10.1002/PROS.21246

https://api.crossref.org/works/10.1002/PROS.21246

13 July 2024

The assessment of treatment outcomes in metastatic prostate cancer: changing endpoints

28

1 reference

10.1002/PROS.21246

https://api.crossref.org/works/10.1002/PROS.21246

13 July 2024

Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer

29

1 reference

10.1002/PROS.21246

https://api.crossref.org/works/10.1002/PROS.21246

13 July 2024

Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate

30

1 reference

10.1002/PROS.21246

https://api.crossref.org/works/10.1002/PROS.21246

13 July 2024

Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer

31

1 reference

10.1002/PROS.21246

https://api.crossref.org/works/10.1002/PROS.21246

13 July 2024

Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy.

32

1 reference

10.1002/PROS.21246

https://api.crossref.org/works/10.1002/PROS.21246

13 July 2024

Prostate-specific antigen doubling time before onset of chemotherapy as a predictor of survival for hormone-refractory prostate cancer patients

34

1 reference

10.1002/PROS.21246

https://api.crossref.org/works/10.1002/PROS.21246

13 July 2024

C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trial

35

1 reference

10.1002/PROS.21246

https://api.crossref.org/works/10.1002/PROS.21246

13 July 2024

Identifiers

10.1002/PROS.21246

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20842666%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20842666%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q85032624&oldid=2203264657"